B
Busyamas Chewaskulyong
Researcher at Chiang Mai University
Publications - 25
Citations - 11902
Busyamas Chewaskulyong is an academic researcher from Chiang Mai University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 20 publications receiving 9459 citations. Previous affiliations of Busyamas Chewaskulyong include Chungbuk National University.
Papers
More filters
Journal ArticleDOI
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka +19 more
TL;DR: Gefit inib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia and the presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.
Journal ArticleDOI
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Jean-Charles Soria,Yuichiro Ohe,Johan Vansteenkiste,Thanyanan Reungwetwattana,Busyamas Chewaskulyong,Ki Hyeong Lee,Arunee Dechaphunkul,Fumio Imamura,Naoyuki Nogami,Takayasu Kurata,Isamu Okamoto,Caicun Zhou,Byoung Chul Cho,Ying Cheng,Eun Kyung Cho,Pei Jye Voon,David Planchard,Wu Chou Su,Jhanelle E. Gray,Siow-Ming Lee,Rachel Hodge,Marcelo Marotti,Yuri Rukazenkov,Suresh S. Ramalingam +23 more
TL;DR: Osimertinib showed efficacy superior to that of standard EGFR‐TKIs in the first‐line treatment of EGFR mutation–positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events.
Journal ArticleDOI
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
Suresh S. Ramalingam,Johan Vansteenkiste,David Planchard,Byoung Chul Cho,Jhanelle E. Gray,Yuichiro Ohe,Caicun Zhou,Thanyanan Reungwetwattana,Ying Cheng,Busyamas Chewaskulyong,R. Shah,Manuel Cobo,Ki Hyeong Lee,Parneet Cheema,Marcello Tiseo,Thomas John,Meng Chih Lin,Fumio Imamura,Takayasu Kurata,A. Todd,Rachel Hodge,M. Saggese,Yuri Rukazenkov,Jean-Charles Soria,Jean-Charles Soria,Jean-Charles Soria,Flaura Investigators +26 more
TL;DR: Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those whoreceived a comparator EGFR-TKI.
Journal ArticleDOI
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
S.S. Ramalingam,Jhanelle E. Gray,Yuichiro Ohe,Byoung Chul Cho,Johan Vansteenkiste,C. Zhou,Thanyanan Reungwetwattana,Ying Cheng,Busyamas Chewaskulyong,Riyaz Shah,K.H. Lee,Parneet Cheema,M. Tiseo,Thomas John,Meng-Chih Lin,Fumio Imamura,Rachel Hodge,Yuri Rukazenkov,Jean-Charles Soria,David Planchard +19 more
TL;DR: Osimertinib significantly improved OS vs comparator EGFR-TKI in the phase III FLAURA study, and the safety profile appears consistent with previously reported data.
Journal ArticleDOI
LBA2_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
S.S. Ramalingam,Thanyanan Reungwetwattana,Busyamas Chewaskulyong,Arunee Dechaphunkul,K.H. Lee,Fumio Imamura,Naoyuki Nogami,Yuichiro Ohe,Ying Cheng,Byoung Chul Cho,E.K. Cho,Johan Vansteenkiste,P.J. Voon,C. Zhou,Jhanelle E. Gray,Rachel Hodge,Yuri Rukazenkov,J-C. Soria +17 more